Quantum Leap Energy (QLE), the nuclear fuel subsidiary of ASP Isotopes, has signed two separate agreements in the first quarter of 2026 to move HALEU production — the high-assay low-enriched uranium that powers next-generation reactors — from the research phase into commercial reality. It is a tangible step forward in a market where Western supply remains nearly nonexistent.
The first agreement was signed in February with the South African Nuclear Energy Corporation (Necsa): a Pre-Implementation Services Contract that formally launches operational collaboration on the research, development, and future commercial production of HALEU at the Pelindaba nuclear site. QLE will bring its proprietary enrichment technologies to the table, while Necsa contributes established infrastructure and a strategic position across the global nuclear supply chain. The agreement is the direct evolution of a previously announced MOU between ASP Isotopes’ South African subsidiary and Necsa, elevating the partnership to a contractual and operational level. Necsa is widely regarded as a world leader in nuclear research and technology. The choice of Pelindaba is deliberate: the site already hosts regulatory expertise and physical infrastructure that QLE would not need to build from scratch.
In March, QLE signed a non-binding memorandum of understanding with a large, publicly listed US energy company that operates active nuclear power plants. The American firm will evaluate options to support QLE’s plans to establish advanced nuclear fuel cycle facilities in the United States, including plants to produce HALEU and LEU+, as well as uranium conversion and deconversion services. The MOU also outlines potential terms of financial support ahead of definitive enriched uranium supply agreements. The counterparty’s name has not been disclosed, but the fact that it is an operator with plants already in service signals genuine, not speculative, demand.
The market context explains why these agreements make sense right now. HALEU is enriched to up to 19.75% U-235, compared with roughly 5% for conventional LEU, and it is the fuel required by the vast majority of SMR projects and advanced reactor designs currently under development. The US Department of Energy estimates that by 2035 the country will need 40 metric tons of HALEU per year to sustain its commercial nuclear sector, with projections rising to 500 metric tons annually by 2050. No Western producer currently operates at commercial scale. QLE aims to fill that gap with its Quantum Enrichment (QE) technology, a proprietary laser-based process the company believes can enrich heavy isotopes at lower cost than conventional centrifuge methods. Development of the QE technology is now being translated into physical specifications for equipment and systems.
QLE is also pursuing an independent listing, separate from parent company ASP Isotopes. Funding raised between 2023 and 2026 is considered sufficient to cover the current development programme. If the roadmap holds — operational agreements in South Africa, facilities in the US, laser technology moving into the prototyping phase — QLE could reach its IPO with a fuel supply chain already partially structured across two continents. For the SMR market, which is desperately short of fuel suppliers outside Russia, that would represent a meaningful shift in the landscape.
